GlobalData on MSN9h
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
ophthalmologyadvisor11h
In Diabetic Eye Disease, Loss to Follow-Up Linked With Race, Distance From Care
Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.
Too Old to Operate13h
Glucose-Lowering Mechanisms of PPARG in Diabetic Retinopathy
The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...
nationthailand15h
Google, Perceptra offer AI-powered diabetic retinopathy screening
Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...
5 diabetes symptoms you can spot on your hands and feet
Diabetes, which affects 4% of adults globally, can cause severe complications such as kidney disease and nerve damage.
BioWorld4d
New APOL1 inhibitors disclosed in Maze Therapeutics patent
Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy, ...
KTEN5d
FDA Approves Susvimo for Diabetic Macular Edema
The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
Business Wire6d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...